.png "SAGE Therapeutics (NASDAQ: SAGE)")
Oppenheimer analyst Jay Olson maintained a Buy rating on SAGE Therapeutics (SAGE) yesterday and set a price target of $170. The company’s shares closed yesterday at $165.52, close to its 52-week high of $177.14.
Olson said:
“SAGE provided a business update along with 1Q results addressing several areas of interest, including launch plans for Zulresso (IV brexanolone) and an R&D portfolio prioritization process to optimize pipeline investments. We’re encouraged by the portfolio approach as SAGE is well funded with ~$1.4B in cash ending 1Q but faces multiple new indications and new molecules from which to select the most attractive investment opportunities including 1) new indications for SAGE-217 with results from the Ph2 ARCHWAY study in bipolar depression expected in July, 2) SAGE-718 NMDA receptor modulator which offers potential for cognitive benefits in various disorders, 3) SAGE-324 next-generation GABA receptor modulator for neurologic conditions, and 4) another PPD study requred for EU approval of Zulresso. We maintain Outperform; details inside.”
According to TipRanks.com, Olson is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -6.1% and a 36.4% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Enanta Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for SAGE Therapeutics with a $211.73 average price target, representing a 27.9% upside. In a report issued on April 25, Jefferies also initiated coverage with a Buy rating on the stock with a $195 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $177.14 and a one-year low of $79.88. Currently, SAGE Therapeutics has an average volume of 529.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
